semaglutide oral or injection ACC 2025: Reduces Cardiovascular Events by 14% at 4 Years Novo Nordisk launched an oral

IGF-1's primary role is mediating the effects of Growth Hormone (GH)

The extended half-life is achieved through structural modifications to the peptide molecule, including fatty acid conjugation, which promotes binding to albumin in the bloodstream and slows clearance

Many individuals following either approach build routines around: Daily multivitamin support Protein-focused nutrition Hydration and electrolyte intake Targeted nutrients when needed The exact supplements often differ between GLP-1 users and bariatric patients because nutritional needs and digestion patterns are not identical

The longest and largest trial of GLP-1 receptor agonists in patients with atherosclerotic cardiovascular disease has demonstrated that semaglutide results in improved cardiovascular outcomes independent of baseline adiposity and over a wide range of treatment-induced weight loss